Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy may let some esophageal cancer patients skip major surgery

NCT ID NCT07317609

Recruiting now Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Jun 11, 2026 · Updated 23 times

Summary

This study tests whether giving chemotherapy plus immunotherapy before treatment can shrink esophageal tumors enough to remove them with an endoscope (a thin tube down the throat) instead of major surgery. About 60 adults with early-stage esophageal cancer will receive two or more cycles of the drug combination. If the tumor shrinks completely, doctors may remove it endoscopically, preserving the esophagus. The goal is to see if this approach is safe and feasible, reducing the need for esophagectomy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Zhongshan Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)